Intranasal Ketorolac Tromethamine

Phase 3Small molecule

Intranasal Ketorolac Tromethamine is one of 7 small molecule programs targeting Nerve Block. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nerve BlockNot yet recruiting

Nerve BlockPhase 3

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Nerve Block

#DrugCompanyPhaseTrials

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Phase 3

3 2

Intranasal Ketorolac Tromethamine

TTehran University of Medical Sciences

Phase 3

1 3

Esmeron

Merck & Co.

Preclinical

1 4

Marcaine

UUniversity of Chicago

Phase 1

1 5

Bupivacain

IIstanbul University

Preclinical

2 6

Tegileridine

XXin Chen

Preclinical

1 7

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Colic1 trial

Atomized Intranasal Vs Intravenous Ketorolac in Acute Renal Colic Pain Management.

Completed·OOman Medical Speciality Board·Phase 2/3·NCT04441762·171 enrolled

Nerve Block1 trial

Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain

Not yet recruiting·TTehran University of Medical Sciences·Phase 3·NCT07305883·64 enrolled

Major Abdominal Surgery1 trial

Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery

Completed·EEgalet Ltd·Phase 3·NCT00266786·321 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Intranasal Ketorolac Tromethamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal Ketorolac Tromethamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal Ketorolac Tromethamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tehran University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTehran University of Medical Sciences

Intranasal Ketorolac Tromethamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Colic1 trial

Nerve Block1 trial

Major Abdominal Surgery1 trial

References

Drug Info

Quick Facts

Related News